[{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"AAV-AQP1","moa":"Aquaporin-1 (AQP1)","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Sanofi"},{"orgOrder":0,"company":"Palacky University","sponsor":"CB21 Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CZECH REPUBLIC","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Palacky University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Palacky University \/ CB21 Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Palacky University \/ CB21 Pharma"},{"orgOrder":0,"company":"Amyndas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AMY-101","moa":"Complement C3","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Amyndas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amyndas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amyndas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RXRG001","moa":"hAQP1 overexpression","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Injection","sponsorNew":"RiboX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RiboX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RXRG001","moa":"hAQP1 overexpression","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RiboX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RiboX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RXRG001","moa":"hAQP1 overexpression","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RiboX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RiboX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Sanidad de Castilla y Le\u00f3n | University of Valladolid | CRMR Castilla y Le\u00f3n | Citospin","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Bone Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Implant","sponsorNew":"Red de Terapia Celular \/ Sanidad de Castilla y Le\u00f3n | University of Valladolid | CRMR Castilla y Le\u00f3n | Citospin","highestDevelopmentStatusID":"7","companyTruncated":"Red de Terapia Celular \/ Sanidad de Castilla y Le\u00f3n | University of Valladolid | CRMR Castilla y Le\u00f3n | Citospin"},{"orgOrder":0,"company":"Augusta University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Mighteaflow","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augusta University \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Augusta University \/ GSK"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"P-552","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Complex Science","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CS-002","moa":"mTOR","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Complex Science","highestDevelopmentStatusID":"7","companyTruncated":"Applied Biology \/ Complex Science"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : CS-002 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Canities.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 10, 2025

                          Lead Product(s) : CS-002

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Complex Science

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 09, 2025

                          Lead Product(s) : RXRG001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : RXRG001 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : RXRG001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 30, 2023

                          Lead Product(s) : AAV-AQP1

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sanofi

                          Deal Size : $30.0 million

                          Deal Type : Financing

                          blank

                          05

                          Palacky University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Palacky University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Chronic Periodontitis.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 11, 2022

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : CB21 Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          HysensBio

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          HysensBio

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dentin Sensitivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 18, 2021

                          Lead Product(s) : KH001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : AMY-101 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gingivitis.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 03, 2018

                          Lead Product(s) : AMY-101

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : PerioSept (Taurolidine) is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Periodontitis.

                          Product Name : PerioSept

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 10, 2014

                          Lead Product(s) : Taurolidine

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Augusta University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Augusta University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Mighteaflow is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 24, 2012

                          Lead Product(s) : Mighteaflow

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Red de Terapia Celular

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Red de Terapia Celular

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Autologous Bone Mesenchymal Stem Cell

                          Therapeutic Area : Dental and Oral Health

                          Study Phase : Phase I/ Phase II

                          Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Autologous Bone Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Maxillary Cyst.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 08, 2011

                          Lead Product(s) : Autologous Bone Mesenchymal Stem Cell

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank